Cargando…
Alpha-1 antitrypsin deficiency research and emerging treatment strategies: what’s down the road?
Intravenous infusion of alpha-1 antitrypsin (AAT) was approved by the United States Food and Drug Administration (FDA) to treat emphysema associated with AAT deficiency (AATD) in 1987 and there are now several FDA-approved therapy products on the market, all of which are derived from pooled human pl...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8367209/ https://www.ncbi.nlm.nih.gov/pubmed/34408832 http://dx.doi.org/10.1177/20406223211014025 |